News Sentiment

ACIU sentiment intelligence

AC Immune Ltd news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 56 Balanced news tone 49 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 2.39 Week of 10 Jul 2026
Weighted tone 56/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

81/100 classification confidence.

Company focus 41

directly relevant articles

Source quality 3

high-authority source matches

Trend context Trend inactive

-4.8% over one week, +3.5% over four weeks, trend inactive, and near fair-value range.

Latest direct headline Positive

AC Immune to Showcase Neurodegenerative Disease Pipeline with Three Presentations at AAIC® 2026

Market Reaction

Price moving ahead of tone

66/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 81/100 classification
One-week reaction -4.8% Price reacting lower
Trend fit Trend inactive 3.5% over four weeks
Fair value -18.6% Near fair-value range

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 14
Neutral 33
Negative 2

Relevance

Why the article matched

Direct first
Direct company coverage 41
Industry context 8
Sector context 0

Sources

Coverage mix

Publishers
Market source 12
Stock Titan 10
TradingView 10
Seeking Alpha 3
Investing.com 3
MT Newswires 2
TradingKey 2
simplywall.st 2

Event Lens

What the news is about

Classified themes
Market update 29
Earnings 16
Deals and strategy 2
Analyst action 1
Balance sheet 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 49
Market source Direct company coverage

AC Immune to Showcase Neurodegenerative Disease Pipeline with Three Presentations at AAIC® 2026

AC Immune SA announced it will present three times at the Alzheimer's Association International Conference® 2026, highlighting its Morphomer®-based small molecule approach for neurodegenerative diseases. The presentations will cover encouraging early human imaging data for a TDP-

Tone
Positive 73/100
Event
Market update
Published
08 Jul 2026 13:14
Source
Market source
Stock Titan Direct company coverage

AC Immune brings three neurodegeneration studies to AAIC 2026

AC Immune (NASDAQ: ACIU) will present three pipeline studies at the Alzheimer's Association International Conference (AAIC) 2026, taking place from July 12-15 in London, UK. The presentations will cover a first-in-class TDP-43 PET tracer, a brain-penetrant NLRP3 inhibitor, and an

Tone
Neutral 50/100
Event
Market update
Published
07 Jul 2026 11:10
Source
Stock Titan
Investing.com Direct company coverage

H.C. Wainwright reiterates AC Immune stock rating on trial data

H.C. Wainwright reiterated a Buy rating and $12.00 price target on AC Immune SA (NASDAQ:ACIU) following interim 12-month data from its ABATE trial for prodromal Alzheimer’s disease. The ACI-24 drug demonstrated safety and tolerability, with detected anti-Abeta antibody responses.

Tone
Positive 70/100
Event
Analyst action
Published
01 Jul 2026 11:40
Source
Investing.com
TradingView Direct company coverage

Price to earnings forward of AC Immune SA – DUS:IMR

This article provides financial data for AC Immune SA (DUS:IMR) focusing on its forward price-to-earnings ratio. It indicates that the market was closed at the time of publication and no trades had occurred. The content is primarily a data placeholder within the TradingView platf

Tone
Neutral 50/100
Event
Earnings
Published
01 Jul 2026 02:38
Source
TradingView
TradingView Direct company coverage

Price to sales forward of AC Immune SA – NASDAQ:ACIU

This article provides a brief financial overview for AC Immune SA (NASDAQ: ACIU), focusing on its forward price-to-sales ratio. It indicates the stock market for ACIU is currently closed with no trades. The content primarily shows the navigation and structure of a financial data

Tone
Neutral 50/100
Event
Market update
Published
01 Jul 2026 00:38
Source
TradingView
Stock Titan Direct company coverage

Takeda-backed AC Immune (NASDAQ: ACIU) reports ACI-24 Alzheimer’s trial update

AC Immune (NASDAQ: ACIU) announced interim 12-month data from the first three cohorts of its Phase 1b/2 ABATE trial for ACI-24, an anti-amyloid beta active immunotherapy for prodromal Alzheimer's disease. The therapy was generally safe and well tolerated in 74 patients, with no A

Tone
Positive 66/100
Event
Market update
Published
30 Jun 2026 13:10
Source
Stock Titan
Stock Titan Direct company coverage

AC Immune’s Alzheimer’s vaccine shows antibody response in 74 patients

AC Immune (NASDAQ: ACIU) reported positive 12-month interim data from its Phase 1b/2 ABATE trial of ACI-24 in 74 patients with prodromal Alzheimer's disease. The active immunotherapy was found to be generally safe and well-tolerated, inducing anti-Abeta antibody responses across

Tone
Positive 73/100
Event
Market update
Published
30 Jun 2026 11:10
Source
Stock Titan
GlobeNewswire Direct company coverage

AC Immune Reports Interim 12-Month Data from Phase 1b/2 ABATE Trial of ACI-24 in Prodromal Alzheimer’s Disease

AC Immune announced interim 12-month data from the first three cohorts of its Phase 1b/2 ABATE trial, evaluating ACI-24 in patients with prodromal Alzheimer’s disease. The ACI-24 anti-amyloid beta active immunotherapy was generally safe and well-tolerated, showing anti-Abeta anti

Tone
Positive 67/100
Event
Market update
Published
30 Jun 2026 11:10
Source
GlobeNewswire
TradingView Direct company coverage

Price to earnings forward of AC Immune SA – NASDAQ:ACIU

This article provides financial information for AC Immune SA (ACIU) on the Nasdaq Stock Market, specifically focusing on its price-to-earnings forward ratio. The content appears to be a stub or a section of a larger financial data service, showing market data and company details

Tone
Neutral 50/100
Event
Earnings
Published
30 Jun 2026 00:41
Source
TradingView
TradingView Direct company coverage

Enterprise value to EBITDA forward of AC Immune SA – NASDAQ:ACIU

This article provides information on the enterprise value to EBITDA forward for AC Immune SA (NASDAQ: ACIU). The content appears to be a financial data snippet from TradingView, offering a snapshot of this specific financial metric for the company.

Tone
Neutral 50/100
Event
Market update
Published
29 Jun 2026 00:40
Source
TradingView
TradingView Direct company coverage

Price to book forward of AC Immune SA – NASDAQ:ACIU

This article provides a brief mention of AC Immune SA (NASDAQ: ACIU) and its "Price to book forward" metric. It appears to be a stub or a section from a larger financial data platform like TradingView, lacking detailed analysis or commentary. The content primarily lists navigatio

Tone
Neutral 50/100
Event
Market update
Published
28 Jun 2026 09:10
Source
TradingView
TradingView Direct company coverage

Enterprise value to revenue forward of AC Immune SA – NASDAQ:ACIU

The article focuses on AC Immune SA (NASDAQ:ACIU) and its enterprise value to revenue forward metric. It appears to be an entry point to financial data on TradingView, providing an overview of the company's financials for investors and analysts interested in pharmaceutical stocks

Tone
Neutral 50/100
Event
Earnings
Published
28 Jun 2026 01:10
Source
TradingView
TradingView Direct company coverage

Enterprise value to EBIT forward of AC Immune SA – NASDAQ:ACIU

This article provides financial data for AC Immune SA (NASDAQ: ACIU), specifically focusing on its enterprise value to EBIT forward. It indicates whether the market is currently open or closed and the trading status. The content primarily serves as a data point within a financial

Tone
Neutral 50/100
Event
Market update
Published
27 Jun 2026 11:40
Source
TradingView
TradingView Direct company coverage

ACIU Forecast — Price Target — Prediction for 2027

This article provides an AC Immune SA (ACIU) stock forecast and price target for 2027 based on analyst opinions. It details the company's current stock performance, market capitalization, earnings, revenue, and other financial metrics. The article also includes frequently asked q

Tone
Positive 61/100
Event
Earnings
Published
25 Jun 2026 12:10
Source
TradingView
TradingKey Direct company coverage

AC Immune SA (ACIU) Earnings Forecast: Future EPS & Revenue Growth Estimates

AC Immune SA (ACIU) has an earnings forecast score of 9.50, ranking 4th in its industry, with analysts assigning a "Strong Buy" rating and an average price target of $8.50. The company's expected revenue for the next quarter is $46.29M, and its previous quarter's EPS was -$0.18,

Tone
Positive 71/100
Event
Earnings
Published
18 Jun 2026 15:10
Source
TradingKey
TradingKey Direct company coverage

AC Immune SA (ACIU) Valuation: PE, PB & Fair Value Analysis

This article provides a valuation analysis for AC Immune SA (ACIU), indicating the company's valuation score is 8.02, ranking 174th in the Biotechnology & Medical Research industry. It highlights the current P/E ratio of -2.91, noting it is significantly below its recent high and

Tone
Positive 58/100
Event
Market update
Published
18 Jun 2026 15:10
Source
TradingKey
Stock Titan Direct company coverage

AC Immune (ACIU) director receives new RSU and stock option grants

AC Immune SA director Renee Aguiar-Lucander received equity compensation awards, specifically a restricted share unit grant of 16,568 common shares and options for 38,889 common shares, under the company's 2016 Stock Option and Incentive Plan. These awards were made on June 11, 2

Tone
Neutral 50/100
Event
Market update
Published
16 Jun 2026 02:39
Source
Stock Titan
Stock Titan Direct company coverage

AC Immune (ACIU) director receives restricted share units and options grant

AC Immune SA director Roy Ervin Twyman was granted 16,568 restricted share units and options over 38,889 common shares on June 11, 2026, as part of his compensation under the company's 2016 Stock Option and Incentive Plan. The options have an exercise price of $2.62 per share, wi

Tone
Neutral 50/100
Event
Market update
Published
15 Jun 2026 11:39
Source
Stock Titan
Stock Titan Direct company coverage

AC Immune (ACIU) grants RSUs and stock options to director Buetler

AC Immune SA (ACIU) director Monika Buetler received equity awards comprising 17,751 restricted share units and options for 41,667 common shares. These grants, made on June 11, 2026, are part of her compensation under the company's 2016 Stock Option and Incentive Plan and increas

Tone
Neutral 50/100
Event
Market update
Published
15 Jun 2026 10:39
Source
Stock Titan
Stock Titan Direct company coverage

[Form 4] AC Immune SA Insider Trading Activity

AC Immune SA director June Carl Howard reported new equity compensation grants on June 11, 2026. She received 16,568 common shares as a restricted share unit grant and share options for 38,889 common shares with an exercise price of $2.62 per share. These awards represent compens

Tone
Neutral 50/100
Event
Market update
Published
15 Jun 2026 10:39
Source
Stock Titan
Stock Titan Direct company coverage

AC Immune (ACIU) interim CEO Martin Zuegel granted RSUs and stock options

AC Immune SA's interim CEO, Martin Zuegel, received equity compensation awards on June 11, 2026, including 33,136 restricted share units and options for 77,778 common shares. The options have an exercise price of $2.6200 per share, will fully vest on June 10, 2027, and expire on

Tone
Neutral 50/100
Event
Market update
Published
15 Jun 2026 10:39
Source
Stock Titan
Market source Direct company coverage

AC Immune to Receive Research Grant from Goradia Family for Development of ACI-7104 in Parkinson’s Disease

AC Immune SA announced it will receive a $4 million research grant from The Vijay and Marie Goradia Charitable Foundation. This grant will support the extension of Part 1 of the ongoing Phase 2 VacSYn trial for ACI-7104, an anti-alpha-synuclein active immunotherapy for early Park

Tone
Positive 90/100
Event
Market update
Published
12 Jun 2026 21:39
Source
Market source
Market source Direct company coverage

AC Immune Presents New Phase 1 Data Indicating Higher Uptake of TDP-43 PET Tracer ACI-19626 in Patients with ALS

AC Immune SA announced new preliminary Phase 1 data demonstrating higher uptake of its TDP-43 PET tracer ACI-19626 in the brains of patients with amyotrophic lateral sclerosis (ALS) compared to healthy controls. The results, presented at the 2026 TDP43 Summit, indicate the tracer

Tone
Positive 72/100
Event
Earnings
Published
12 Jun 2026 00:09
Source
Market source
Stock Titan Direct company coverage

AC Immune (NASDAQ: ACIU) AGM clears 2025 loss, extends capital band and boosts liquidity runway

AC Immune shareholders approved all proposals at the June 2026 Annual General Meeting, including the 2025 financial statements and compensation report, despite reporting an IFRS loss of CHF 70.4 million on revenues of CHF 3.6 million, increasing accumulated losses to CHF 424.441

Tone
Neutral 50/100
Event
Balance sheet
Published
11 Jun 2026 21:09
Source
Stock Titan